Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 10/20 | 0.58 |
| ▸ | GALR1 | P47211 | 7/20 | 0.58 |
| ▸ | IDH2 | P48735 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 2/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242634 | 0.86 | GALR2 (0.56) | GALR2GALR1IDH2MAPTAPAF1 | |
| SCHEMBL3240927 | 0.86 | GALR2 (0.77) | GALR2GALR1MAPTAPAF1GAA | |
| SCHEMBL3237771 | 0.84 | GALR2 (0.54) | GALR2GALR1IDH2MAPTPHGDH | |
| SCHEMBL3245932 | 0.83 | GALR2 (0.61) | GALR2GALR1MAPTNPSR1APAF1 | |
| SCHEMBL3241078 | 0.81 | GALR2 (0.57) | GALR2GALR1MAPTAPAF1GAA | |
| SCHEMBL3240588 | 0.80 | GALR2 (0.59) | GALR2GALR1MAPTAPAF1GAA | |
| SCHEMBL3243408 | 0.79 | GALR2 (0.81) | GALR2GALR1 | |
| SCHEMBL3233075 | 0.79 | GALR2 (0.81) | GALR2GALR1 | |
| SCHEMBL3241392 | 0.78 | GALR2 (0.59) | GALR2GALR1MAPTAPAF1GAA | |
| SCHEMBL3266094 | 0.77 | GALR2 (0.55) | GALR2GALR1MAPTAPAF1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2007-11-08 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| EP-1363638-A2 | USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | Synaptic Pharmaceutical Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
| WO-2002060392-A2 | USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885IDH2 2790/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885IDH2 2790/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885IDH2 1984/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885IDH2 3889/4885 |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885IDH2 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.